Intraperitoneal monoclonal antibody ovarian cancer March March phase II study patients ovarian cancer doses IP monoclonal antibody tumor cell-surface antigen Myelosuppression escalation administered activity mCi antibody peritoneal cavity circulation Maximum blood activity hours IP injection mean injected activity range circulation radiation bone marrow antibody blood radiation dose Medical Internal Radiation Dose MIRD formulation activity patients blood Myelosuppression blood radiation marrow cGy excessive myelosuppression modest radiation doses antibody uptake bone attempt absorption patients intravenous IV infusion EDTA Sinclair Ltd Godalming United Kingdom urinary excretion mean injected activity Fourteen patients assessable tumor laparoscopy Tumor regression patient palliation ascites patient 